 |
Therapeutics | Medical Technology | Diagnostics |
"The Wellington life sciences team has been a great resource in our first round of financing. We were very impressed by the speed and efficiency with which they processed this deal, put the consortium together and conducted due diligence. Wellington has also been highly supportive in the fine-tuning of our commercialization plans. Above all, with this deal, we are gaining access to Wellington’s world-class network of relevant industry experts and clinical opinion leaders – which is a tremendous advantage for our company."
Jean-Marc Wismer, CEO, Sensimed
Wellington contact:
Erich Schlick
Swiss-based Sensimed AG has developed a new, patented diagnostic test system that will significantly improve identification and treatment of glaucoma – a disease that afflicts some 70 million people worldwide and is the second-most frequent cause of blindness. Intraocular pressure, which can occur both during the day as well as at night with high individual variation, has been identified as a high risk factor for glaucoma. While repeated single measurements of intraocular pressure outside of typical doctors’ office hours have thus far been highly labor-intensive and often required hospitalization, Sensimed’s core product CLS IOP-24 enables non-invasive, precise and cost-effective measurements around the clock. The data obtained will greatly improve prevention of glaucoma and enable custom-tailored therapies for patients. Sensimed was established in 2003 as a spin-off from the renowned EPFL Technical University in Lausanne, and has been headed up by Jean-Marc Wismer since 2007.
Sensimed AG
PSE-C 218
CH-1015 Lausanne
Switzerland
Website: www.sensimed.ch
CEO: Jean-Marc Wismer
 |
Wellington Partners portfolio company Proximic offers
a publisher widget that shows content from the internet that is related to the current page. You can see it in action below. Please visit www.proximic.com for more information.